Literature DB >> 2117116

The role of surgery in diagnosis and treatment of mediastinal malignancies.

H Neef1.   

Abstract

Primary mediastinal malignancies should be treated aggressively using a multidisciplinary approach since some are curable. Surgery is indicated in almost all cases of mediastinal masses with the exception of malignant lymphomas. The question of operability must be placed at the beginning of diagnostic measures in a mediastinal mass. Exact decisions about local operability are often only possible after thoracotomy. Long lasting diagnostic maneuvers are therefore to be avoided. Histological assessment of masses in the middle or anterior mediastinum is possible by mediastinoscopy or other methods. Thus in malignant lymphomas or metastases thoracotomy can be avoided. In the other mediastinal spaces exact histology remains unknown until thoracotomy. If exploration shows inoperability, mass reduction is performed to decrease the space-taking process and to provide better chances for radiotherapy and chemotherapy. Primary radiotherapy and/or chemotherapy are indicated in malignant lymphomas and germ cell tumors. After these measures the indication for surgical excision in tumors has to be proved. X-ray screening techniques need to be improved to aid in early detection, higher extirpation rates, and thus better chances for cure. Because the amount of cases in individual departments is low multicenter collaboration will be required to define the optimal combined modality approach.

Entities:  

Mesh:

Year:  1990        PMID: 2117116     DOI: 10.1007/bf02718256

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  12 in total

1.  A multidisciplinary approach to primary nonseminomatous germ cell tumors of the mediastinum.

Authors:  P H Kay; F C Wells; P Goldstraw
Journal:  Ann Thorac Surg       Date:  1987-12       Impact factor: 4.330

2.  Replacement of the superior vena cava with polytetrafluoroethylene grafts combined with resection of mediastinal-pulmonary malignant tumors. Report of thirteen cases.

Authors:  P Dartevelle; A Chapelier; M Navajas; P Levasseur; A Rojas; J Khalife; E Lafontaine; M Merlier
Journal:  J Thorac Cardiovasc Surg       Date:  1987-09       Impact factor: 5.209

3.  Surgical treatment of mediastinal tumors: a 40 year experience.

Authors:  A R Wychulis; W S Payne; O T Clagett; L B Woolner
Journal:  J Thorac Cardiovasc Surg       Date:  1971-09       Impact factor: 5.209

4.  [Successful removal of mediastinal tumors that were inoperable at the first intervention].

Authors:  T Tóth; I Szöts; A Záborsky; P Hazslinsky
Journal:  Zentralbl Chir       Date:  1987       Impact factor: 0.942

5.  Primary malignant mediastinal tumors.

Authors:  R B Adkins; M D Maples; J D Hainsworth
Journal:  Ann Thorac Surg       Date:  1984-12       Impact factor: 4.330

6.  [Tumors of the anterior mediastinum--surgical treatment and prognosis].

Authors:  U Engel; V Bay; C Mier
Journal:  Chirurg       Date:  1987-05       Impact factor: 0.955

7.  [The diagnosis and therapy of mediastinal tumors (author's transl)].

Authors:  G Salzmann; R Kuntz; F Spelsberg
Journal:  MMW Munch Med Wochenschr       Date:  1976-12-17

8.  Selective operative approach for diagnosis and treatment of anterior mediastinal masses.

Authors:  M K Ferguson; E Lee; D B Skinner; A G Little
Journal:  Ann Thorac Surg       Date:  1987-12       Impact factor: 4.330

9.  Effective treatment for malignant mediastinal teratoma.

Authors:  D Parker; C P Holford; R H Begent; E S Newlands; G J Rustin; A R Makey; K D Bagshawe
Journal:  Thorax       Date:  1983-12       Impact factor: 9.139

10.  [Space occupying mediastinal processes].

Authors:  M Kahle; D Filler; K H Muhrer; G Fraedrich
Journal:  Chirurg       Date:  1981-10       Impact factor: 0.955

View more
  1 in total

1.  Ectopic thyroid gland on the ascending aorta with a partial pericardial defect: report of a case.

Authors:  Berkant Ozpolat; Orhan Veli Dogan; Gökhan Gökaslan; Selim Erekul; Ertan Yücel
Journal:  Surg Today       Date:  2007-05-28       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.